Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAKAHDI - JAK inhibitors in acquired hemophagocytic syndrome in the ICU
2023-504513-77-00Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ruxolitinib in haemophagocytic lymphohistiocytosis (HLH), sponsored by Assistance publique - Hôpitaux de Paris. Started Oct 2023; status: completed.
02
Drugs
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on 2023-504513-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504513-77-00.